Oncotarget

Research Papers:

Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?

Constantin Lapa _, Stefan Kircher, Andreas Schirbel, Andreas Rosenwald, Saskia Kropf, Theo Pelzer, Thorsten Walles, Andreas K. Buck, Wolfgang A. Weber, Hans-Juergen Wester, Ken Herrmann, Katharina Lückerath

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2017; 8:96732-96737. https://doi.org/10.18632/oncotarget.18235

Metrics: PDF 377 views  |   HTML 666 views  |   ?  


Abstract

Constantin Lapa1, Stefan Kircher2, Andreas Schirbel1, Andreas Rosenwald2, Saskia Kropf3, Theo Pelzer4, Thorsten Walles5, Andreas K. Buck1, Wolfgang A. Weber6, Hans-Juergen Wester7, Ken Herrmann1,8 and Katharina Lückerath1

1Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany

2Institute of Pathology, University of Würzburg, Comprehensive Cancer Center Mainfranken (CCCMF), Würzburg, Germany

3Scintomics GmbH, Fürstenfeldbruck, Germany

4Department of Internal Medicine I, Division of Pulmonology, Universitätsklinikum Würzburg, Würzburg, Germany

5Department of Thoracic Surgery, University Hospital Magdeburg, Magdeburg, Germany

6Molecular Imaging and Therapy Service, Memorial Sloan-Kettering Cancer Center and Weill-Cornell Medical College, New York, New York, USA

7Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany

8Department of Nuclear Medicine, University Hospital Essen, Essen, Germany

Correspondence to:

Constantin Lapa, email: lapa_c@ukw.de

Keywords: PET, CXCR4, [68Ga] pentixafor, pleural mesothelioma, theranostics

Received: March 29, 2017     Accepted: May 15, 2017     Published: May 27, 2017

ABSTRACT

C-X-C motif chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. This study investigated the feasibility of CXCR4-directed imaging with positron emission tomography/computed tomography (PET/CT) using [68Ga]Pentixafor in malignant pleural mesothelioma.

Six patients with pleural mesothelioma underwent [68Ga]Pentixafor-PET/CT. 2′-[18F]fluoro-2′-deoxy-D-glucose ([18F]FDG)-PET/CT (4/6 patients) and immunohistochemistry obtained from biopsy or surgery (all) served as standards of reference. Additionally, 9 surgical mesothelioma samples were available for histological work-up.

Whereas [18F]FDG-PET depicted active lesions in all patients, [68Ga]Pentixafor-PET/CT recorded physiologic tracer distribution and none of the 6 patients presented [68Ga]Pentixafor-positive lesions. This finding paralleled results of immunohistochemistry which also could not identify relevant CXCR4 surface expression in the samples analyzed.

In contrast to past reports, our data suggest widely absence of CXCR4 expression in pleural mesothelioma. Hence, robust cell surface expression should be confirmed prior to targeting this chemokine receptor for diagnosis and/or therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18235